# RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia

> **NCT05405309** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Utah** · enrollment: 5 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** RP-3500
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT05405309
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-09-23
- **Primary completion:** 2023-10-24
- **Final completion:** 2025-01-10
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** This study was terminated due to sponsor de-activation of all programs associated with RP-3500 (camonsertib).
- **Last updated:** 2025-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05405309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05405309, "RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05405309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*